| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 6,022 | -4,650 |
| Net (decrease) increase in cash and cash equivalents | -52,314 | -58,700 |
| Cash and cash equivalents at beginning of period | 144,761 | - |
| Cash and cash equivalents at end of period | 92,447 | - |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)